title: Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma.
abstract: Hypoxia enhances proliferation, angiogenesis, metastasis, chemoresistance, and radioresistance of hepatocellular carcinoma (HCC); suppresses differentiation and apoptosis of HCC; and consequently leads to resistance of transarterial embolization (with or without chemotherapy). Because transarterial embolization contributes to angiogenesis via inducing hypoxia, therapy combined with transarterial embolization and antiangiogenic therapy provides a new strategy for the treatment of HCC. Unfortunately, hypoxia leads to the escape of HCC cells from transarterial embolization and antiangiogenic therapy. Thus combined therapy that induces and targets hypoxia may be of benefit to HCC patients. Because angiogenesis plays an important role in recurrence of HCC after resection, antiangiogenic therapy is beneficial to HCC patients following surgical resection of the tumor.
authors.affiliation: Department of Integrative Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. ilwxz@163.com
authors.forename: Xiong-Zhi
authors.initials: XZ
authors.lastname: Wu
authors.forename: Guang-Ru
authors.initials: GR
authors.lastname: Xie
authors.forename: Dan
authors.initials: D
authors.lastname: Chen
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000098:blood supply / Q000473:pathology / Q000628:therapy*; D015687:Cell Hypoxia / Q000502:physiology; D004621:Embolization, Therapeutic; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000502:physiology; D008113:Liver Neoplasms / Q000098:blood supply / Q000473:pathology / Q000628:therapy*; D009389:Neovascularization, Pathologic / Q000473:pathology / Q000503:physiopathology
chemical_list: D020533:Angiogenesis Inhibitors; D051795:Hypoxia-Inducible Factor 1, alpha Subunit